We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Pharmaceutical Manufacturing May Be Harming Our Water Supply

Pharmaceutical Manufacturing May Be Harming Our Water Supply content piece image
Credit: Pixabay
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

When people take medications, these drugs and their metabolites can be excreted and make their way to wastewater treatment plants. From there, the compounds can end up in waterways. Wastewater from pharmaceutical companies could start off with even larger amounts of these substances. Researchers report that a single pharmaceutical manufacturing facility could be influencing the water quality of one of Europe’s most important rivers.

Wastewater from homes and pharmaceutical manufacturing sites typically goes to treatment plants. Some of the compounds in the water might be biologically active, toxic or persistent, but treatment plants cannot always remove all of the substances before the treated water is discharged into streams or rivers. Little is known about the extent of water contamination from the pharmaceutical industry, in part because companies usually do not disclose details about their manufacturing activities or the identities of the compounds they use. Heinz Singer and colleagues from the Swiss Federal Institute of Aquatic Science and Technology (known as Eawag) wanted to compare compounds in discharged wastewater from two treatment plants near the Rhine River in Switzerland: one that receives only domestic wastewater (WWTP_dom) from homes and small businesses, and one that also receives wastewater from a pharmaceutical manufacturing site (WWTP_ind).

For three months, the team collected daily samples of treated wastewater from the plants and analyzed the substances in them using high-resolution mass spectrometry. Because the pharmaceutical industry typically produces single batches of drugs separated by time, the researchers looked for compounds that showed large variations. They found more of these highly variable compounds in water from WWTP_ind than from WWTP_dom. The team identified 25 compounds as pharmaceutical industry-related substances, including antidepressants and opioids, and their peak levels were much higher in the water from WWTP_ind than from the plant that only handled domestic wastewater. The researchers also detected several of these substances more than 60 miles downstream in the Rhine River, and their levels correlated with those at WWTP_ind. These findings indicate that a single company can impact the drinking water resource for millions of people, the researchers say.

Reference

Anliker et al. (2020) Assessing Emissions from Pharmaceutical Manufacturing Based on Temporal High-Resolution Mass Spectrometry Data. Environmental Science & Technology. DOI: https://doi.org/10.1021/acs.est.9b07085

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.